$7.59
0.152.06%
Last update: Nov 11, 1:38 PM
MapLight Therapeutics Inc
MPLTNASDAQ
The average analyst price target for MapLight Therapeutics is $32.45, 327.4% above the current price. Of 12 analysts, 10 rate it Buy and 2 Hold. Targets range from $13 to $46. The latest change came on Oct 6, 2026, when Guggenheim initiated coverage of MapLight Therapeutics with a Neutral rating.
Price Target Range — 4 Quarters
Analyst Consensus — 12 Analysts
Rating Trend — Last 9 Months
